ECOR · electroCore, Inc.
$6.33
-0.07 (-1.09%)
At close · Jul 22
Going-concern doubt
— flagged May 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Notwithstanding the expected cash flow from operations and expected access to capital from existing and/or future debt and equity sources, the Company’s currently forecasted cash is less than the requirements to fund its operating expenses and capital expenditure requirements, as currently planned, for at least the next 12 months from the date the accompanying condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed May 6, 2026
Market Cap
$52.51M
Shares
8.30M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.33
Open$6.42
Day$6.01–6.51
52W$4.16–10.50
Avg vol 30d97K
Short int204K · 2.5% float · 2.4d
Short vol47%
Last earningsMay 6, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.6 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−0%
below
Price vs 50-day avg
−19%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
34%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−24%
trailing
6-month return
−13%
trailing
YTD return
+41%
this year
Relative strength
−20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $6 — 50d above 200d
Institutional flow
Distributing
3 of 30 funds reported for Jun 30 · net -10.4K sh shares
Insider flow
Distributing
Net -$19.7K over 90 days · 50% sells
Short interest
Falling
2.46% of float · ▼ -1.4% MoM · 2.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
30 holders — mid 3-yr range
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
+27%
Y/Y
Gross margin
87%
expanding
EPS growth
−4%
Y/Y
Free cash flow
$-8.3M
Balance sheet
$116.4K
net cash
Quant / Vol
risk profile
Volatility
91%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
12.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Full-year 2026 revenue
· full year 2026
Initiated
30%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−0%
Neutral
Price vs 50-day avg
−19%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
34%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $6 — 50d above 200d
Institutional flow
Distributing
3 of 30 funds reported for Jun 30 · net -10.4K sh shares
Insider flow
Distributing
Net -$19.7K over 90 days · 50% sells
Short interest
Falling
2.46% of float · ▼ -1.4% MoM · 2.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
30 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $4
Now $6 · 34%
52-wk high $10
vs 200-day avg 0%
vs 50-day avg -19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Number of VA facilities which have purchased prescription gammaCore products | 200 | Q1 FY2026 | — |
| VA headache market penetration | 2.5% | Q1 FY2026 | — |
| VA patients that have received a gammaCore device | 15,000 | Q1 FY2026 | — |
| Adjusted EBITDA net loss non-GAAP | $8.7M | full year ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ECOR
this stock
electroCore, Inc.
|
$52.51M | +41.1% | +27.2% | — | 2.5% |
|
ABT
Abbott Laboratories
|
$175.17B | -19.3% | +5.7% | 28.2 | 1.3% |
|
SYK
Stryker Corp
|
$118.55B | -11.8% | +11.2% | 35.8 | 1.8% |
|
MDT
Medtronic plc
|
$104.82B | -14.1% | +8.4% | 22.0 | 1.5% |
|
BSX
Boston Scientific Corp
|
$63.87B | -54.9% | +5.5% | 18.0 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ECOR | +5.0% | -24.2% | -12.7% | -26.7% | +41.1% |
| SPY | -1.0% | +1.9% | +7.5% | +0.1% | +9.6% |
| vs SPY | +6.0% | -26.1% | -20.2% | -26.8% | +31.5% |